Mike Stocum | Mitochondrial Oncology and Advancing Next-Generation Cancer Therapies
Mike Stocum joins Executive Insights for Life Sciences Innovators to discuss oncology innovation, mitochondrial biology, biotech entrepreneurship, and the development of next-generation cancer therapies.
Prefer audio only? Listen to this episode on Spotify.
Episode Overview
In this episode, Mike Stocum discusses how Bantam Pharmaceutical is developing therapies designed to target cancer cells through their mitochondria. The conversation explores the scientific rationale behind this approach, the challenges of oncology drug development, and the leadership, strategy, and vision required to build innovative biotechnology companies.
Key Themes
- Mitochondria-targeted cancer therapies
- Oncology innovation and drug development
- Emerging approaches to cancer treatment
- Biotech entrepreneurship and company building
- Translating scientific discoveries into therapeutic programs
- The future of oncology therapeutics
Why This Matters for Life Sciences Leaders
The future of oncology depends on continued innovation in how cancer is understood and treated. As biotechnology companies pursue novel therapeutic mechanisms, leaders must balance scientific risk, capital allocation, and long development timelines. The conversation highlights the challenges and opportunities involved in advancing breakthrough therapies while building organizations capable of creating lasting impact for patients.
Guest Link
More from Executive Insights
Explore more conversations with life sciences founders, CEOs, investors, and operators on the Executive Insights for Life Sciences Innovators podcast.
